Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
Primary Purpose
Open Angle Glaucoma, Ocular Hypertension
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Netarsudil/Latanoprost 0.02%/0.005%
GANFORT®
Sponsored by
About this trial
This is an interventional treatment trial for Open Angle Glaucoma
Eligibility Criteria
Inclusion Criteria:
- Must be 18 years of age or older.
- Diagnosis of OAG or OHT in both eyes (OAG in one eye and OHT in the fellow eye is acceptable).
- Subjects insufficiently controlled and/or subjects considered in need for combination therapy by the investigators.
- Medicated intraocular pressure ≥ 17 mmHg in at least one eye and < 28mmHg in both eyes at screening visit.
- Unmedicated (post-washout) IOP >20mmHg in at least one eye and < 36mmHg in both eyes at 2 qualification visits at 08:00 hour, 2-7 days apart. At the second qualification visit, have IOP >17mmHg in at least one eye and < 36mmHg in both eyes at 10:00 and 16:00 hours. Note: For purposes of determining eligibility of subjects to be enrolled, the non-integral IOP mean number will be used. Any non-integral mean IOP number should not be rounded. If only one eye qualifies at the second qualification visit it MUST be the same eye that qualified on the first visit and this will be the study eye for the duration of the study.
- Best corrected visual acuity +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200 or better Snellen visual acuity in each eye).
- Be able and willing to give signed informed consent and follow study instruction.
- Women must be either of non-childbearing potential, or women with childbearing potential and men with reproductive potential must be willing to practice acceptable methods of birth control during the study.
- Women of childbearing potential must have a negative urine pregnancy test within 7 days of first dose of study treatment and agree to use highly effective contraception during the study and for 3 months after the last dose of study medication.
- Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use an effective form of contraception from time of randomization and for 3 months following the last dose of study medication.
- In France, a subject will be eligible for inclusion in this study only if either affiliated to or as a beneficiary of a social security number.
Exclusion Criteria:
Ophthalmic:
- Clinically significant ocular disease (e.g., corneal edema, uveitis, or severe keratoconjunctivitis sicca) which might interfere with interpretation of the study efficacy endpoints or with safety assessments, including subjects with glaucomatous damage so severe that washout of ocular hypotensive medications for 4 weeks or longer if needed is not judged safe as it would put the subject at risk for further vision loss.
- Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma, or narrow angles i.e. Grade 2 Shaffer (Chan 1981) or less extreme narrow angle with complete or partial closure. Note: Previous laser peripheral iridotomy is NOT acceptable.
- Intraocular pressure ≥ 36mmHg (unmedicated) in either eye (individuals who are excluded for this criterion are not allowed to attempt requalification), or use of more than two ocular hypotensive medications within 30 days of screening. Note: fixed dose combination medications, for the purpose of this exclusion criterion, count as one medication. However, subjects currently taking 2 fixed dose combination products are excluded.
- Treatment-naïve subjects.
- Prior treatment with GANFORT® topical eye drops where the subjects IOP did not achieve the target IOP and was considered either a therapeutic failure or to have insufficient response. Subjects currently (immediately prior to screening visit) being treated with GANFORT® are excluded from the study.
- Known hypersensitivity to any component of the investigational formulations to be used (e.g., benzalkonium chloride) or to fluorescein.
- Previous glaucoma intraocular surgery, including SLT or ALT in either eye.
- Refractive surgery in either eye (e.g., radial keratotomy, PRK, LASIK, corneal cross-linking, keratoplasty).
- Ocular trauma within the six months prior to screening, or ocular surgery or non-refractive laser treatment within the three months prior to screening.
- Recent or current evidence of ocular infection or inflammation in either eye. Current evidence of clinically significant blepharitis, conjunctivitis, keratitis, current evidence or history of herpes simplex or zoster keratitis in either eye at screening.
- Use of ocular medication in either eye of any kind within 30 days of screening and throughout the study, with the exception of a) ocular hypotensive medications which must have been the same medication for 30 days prior to screening (which must be washed out according to the provided schedule), b) lid scrubs (which may be used prior to, but not after, screening), c) lubricating drops for dry eye (which may be used throughout the study), as prescribed by the Investigator.
- Mean central corneal thickness greater than 620μm at screening.
Any abnormality preventing reliable Goldmann applanation tonometry of either eye (e.g., keratoconus).
Systemic:
- Clinically significant abnormalities in laboratory tests at screening.
- Known hypersensitivity or contraindication to GANFORT® (Appendix 3 Marketed Product Medication Information Section 4.3) and to β-adrenoceptor antagonists (e.g. Chronic obstructive pulmonary disease or bronchial asthma; abnormally low blood pressure or heart rate; second or third-degree heart block or congestive heart failure, cardiac failure, cardiac shock and severe diabetes).
- Clinically significant systemic disease which might interfere with the study.
- Participation in any investigational study within 30 days prior to screening.
- Systemic medication including corticosteroid containing drugs that could have a substantial effect on IOP which HAVE NOT been maintained at a consistent dose and regime within 30 days prior to screening, and are anticipated to change in dose and/or regime during the study.
- Use of topical steroid containing medications on the face or in or around the eyes will exclude the subject (see Section 5.6 Concomitant Medications).
- Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable and highly effective form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal (1 year without menses with appropriate clinical profile, e.g. age appropriate, > 45 years in the absence of HRT. In questionable cases the subject must have FSH value > 40mIU/mL and an estradiol value < 40pg/mL (< 140pmol/L)) or three months post-surgical sterilization.
- Vulnerable subjects such as minors, adults under legal protection or unable to express their consent (e.g. hospitalized persons in coma), persons deprived of liberty (prisoners from jails), or persons subject to psychiatric care.
Sites / Locations
- State Hospital - University Medical Center Academical Department of Ophthalmology
- Albertgasse 39/10+11
- Hanusch Hospital
- UZ Leuven, campus Gasthuisberg, Herestraat 49, 3000 Leuven
- Faculty Hospital Brno Eye Department
- Glaucoma center Oční klinika VFN a 1. LF UK
- Ophthalmology Service Centre Francois Xavier Michelet CHU Pellegrin
- Centre ophtalmologique Pole vision val d'ouest
- Ophthalmology Service - Batiment R Hospital de la Croix-Rousse
- CHU de Nantes-Hospital Hotel Dieu Ophthalmology Service
- Ophthalmology department Necker University Hospital-Enfants Malades
- University Medical Center Freiburg, Eye Center,Killianstr.5, Freiburg i. Breisgau
- Department of Ophthalmology Clinical Johannes Gutenberg-University Mainz
- Universitats-Augenklinik, Studienzentrum/Clinical Trials in Opthalmology (CTO)
- University Eye Hospital Tuebingen, STC eyetrial at the center for Ophthalmolgy
- Augenarztpraxis Dr. Andreas Bayer
- Budapest Retina Associates
- Department of Ophthalmology Semmelweis University
- University of Debrecen, Clinical Center, Ophthalmology Department
- Clinexpert Gyongyos Kft.
- Ganglion Medical Center
- University of Szeged, Department of Ophthalmology
- Markusovszky University Teaching Hospital
- Ophthalmic Clinic DiNOGMI University Hospital San Martino
- Dept. Ophthalmology, San Raffaele Hospital
- ASST Fatebenefratelli Sacco P.O.L.Sacco
- ASST Santi Paolo e Carlo - Ophthalmic Clinic
- Department of Medicine and Surgery University of Parma
- Ophthamic Clinic of the University of Pavia, IRCCS Foundation San Matteo Policlinic
- AOU Pisana Hospital of Cisanello
- G.B.Bietti Foundation - IRCCS
- Senese University Hospital
- S.C.U Oculistica, Azienda Ospedaliero Universitaria, Città della Salute e della Scienza
- University Eye Clinic Ospedale Maggiore
- Politecnico Gianbattista Rossi AOUI Ospedale Borgo Roma
- Signes Ozolinas Doctor Practice in Ophthalmology
- Latvian American Eye Centre (LAAC)
- P.Stradins Clinical University Hospital, Ophthalmology Clinic
- Riga East University hospital, In-patient Department "Biķernieki", Ophthalmology Clinic
- Professor K. Gibinski University Clinical Centre
- Department of Diagnostics and Microsurgery of Glaucoma
- Military Institute of Medicine Klinika Okulistyki
- Ophthalmic Clinic Jasne Blonia
- Centro de Oftalmologia Barraquer
- Hospital General de Catalunya Ophthalmology Department
- Hospital QuironSalud Barcelona
- Institut Catala de retina (ICR) Glaucoma and Investigation Department
- Hospital General del S.A.S. de Jerez de la Frontera
- Hospital Universitario Reina Sofía de Córdoba
- Centro de Ojos de la Coruña
- Hospital Universitario Virgen Macarena Ophthalmology Department
- Hospital Universitario de Torrevieja Ophthalmology Department
- FISABIO-Oftalmología Médica
- Ophthalmology Department Hospital Universitario Rio Hortega
- Hospital Clinico Universitario Lozano Blesa Zaragoza Ophthalmology department
- Hospital Universitario Miguel Servet Ophthalmology Department
- City Hospitals Sunderland NHS Foundation Trust Sunderland Eye Infirmary
- NHS Grampian Aberdeen Royal Infirmary
- Cambridge University Hospitals NHS Trust
- Ophthalmology Department, Queen Alexandra Hospital
- Mid-Cheshire Hospitals NHS Foundation Trust
- Northwest Anglia NHS Foundation trust Hinchingbrooke Hospital
- Guy's & St Thomas' NHS Foundation Trust Glaucoma Research Area
- King's College Hospital
- Moorfields Eye Hospital NHS
- Western Eye Hospital
- Royal Hallamshire Hospital
- Queen Mary Hospital, King's College Hospital NHS
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Netarsudil/Latanoprost 0.02%/0.005%
GANFORT®
Arm Description
PG324 Ophthalmic Solution (netarsudil 0.02% / latanoprost 0.005%) one drop daily to each eye for 180 days.
GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic solution one drop daily to each eye for 180 days.
Outcomes
Primary Outcome Measures
Mean Diurnal Intraocular Pressure by Goldmann Applanation Tonometry
Comparison of PG324 to Ganfort for mean intraocular pressure at specified timepoints at Week 2, Week 6 and Month 3.
Secondary Outcome Measures
Full Information
NCT ID
NCT03284853
First Posted
August 29, 2017
Last Updated
January 24, 2022
Sponsor
Aerie Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT03284853
Brief Title
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
Official Title
A Prospective, Double-masked, Randomized, Multicenter, Active-controlled, Parallel-group, 6-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to GANFORT® (Bimatoprost 0.03% / Timolol 0.5%) Ophthalmic Solution in Subjects With Elevated Intraocular Pressure (MERCURY 3)
Study Type
Interventional
2. Study Status
Record Verification Date
January 2022
Overall Recruitment Status
Completed
Study Start Date
September 5, 2017 (Actual)
Primary Completion Date
November 6, 2020 (Actual)
Study Completion Date
November 6, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Aerie Pharmaceuticals
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
5. Study Description
Brief Summary
The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02% / 0.005% Ophthalmic Solution, relative to GANFORT® for lowering of intraocular pressure (IOP) in patients with elevated intraocular pressure
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Open Angle Glaucoma, Ocular Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
436 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Netarsudil/Latanoprost 0.02%/0.005%
Arm Type
Experimental
Arm Description
PG324 Ophthalmic Solution (netarsudil 0.02% / latanoprost 0.005%) one drop daily to each eye for 180 days.
Arm Title
GANFORT®
Arm Type
Active Comparator
Arm Description
GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic solution one drop daily to each eye for 180 days.
Intervention Type
Drug
Intervention Name(s)
Netarsudil/Latanoprost 0.02%/0.005%
Intervention Description
Topical sterile ophthalmic solution
Intervention Type
Drug
Intervention Name(s)
GANFORT®
Intervention Description
Topical sterile ophthalmic solution
Primary Outcome Measure Information:
Title
Mean Diurnal Intraocular Pressure by Goldmann Applanation Tonometry
Description
Comparison of PG324 to Ganfort for mean intraocular pressure at specified timepoints at Week 2, Week 6 and Month 3.
Time Frame
Day 90
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Must be 18 years of age or older.
Diagnosis of OAG or OHT in both eyes (OAG in one eye and OHT in the fellow eye is acceptable).
Subjects insufficiently controlled and/or subjects considered in need for combination therapy by the investigators.
Medicated intraocular pressure ≥ 17 mmHg in at least one eye and < 28mmHg in both eyes at screening visit.
Unmedicated (post-washout) IOP >20mmHg in at least one eye and < 36mmHg in both eyes at 2 qualification visits at 08:00 hour, 2-7 days apart. At the second qualification visit, have IOP >17mmHg in at least one eye and < 36mmHg in both eyes at 10:00 and 16:00 hours. Note: For purposes of determining eligibility of subjects to be enrolled, the non-integral IOP mean number will be used. Any non-integral mean IOP number should not be rounded. If only one eye qualifies at the second qualification visit it MUST be the same eye that qualified on the first visit and this will be the study eye for the duration of the study.
Best corrected visual acuity +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200 or better Snellen visual acuity in each eye).
Be able and willing to give signed informed consent and follow study instruction.
Women must be either of non-childbearing potential, or women with childbearing potential and men with reproductive potential must be willing to practice acceptable methods of birth control during the study.
Women of childbearing potential must have a negative urine pregnancy test within 7 days of first dose of study treatment and agree to use highly effective contraception during the study and for 3 months after the last dose of study medication.
Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use an effective form of contraception from time of randomization and for 3 months following the last dose of study medication.
In France, a subject will be eligible for inclusion in this study only if either affiliated to or as a beneficiary of a social security number.
Exclusion Criteria:
Ophthalmic:
Clinically significant ocular disease (e.g., corneal edema, uveitis, or severe keratoconjunctivitis sicca) which might interfere with interpretation of the study efficacy endpoints or with safety assessments, including subjects with glaucomatous damage so severe that washout of ocular hypotensive medications for 4 weeks or longer if needed is not judged safe as it would put the subject at risk for further vision loss.
Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma, or narrow angles i.e. Grade 2 Shaffer (Chan 1981) or less extreme narrow angle with complete or partial closure. Note: Previous laser peripheral iridotomy is NOT acceptable.
Intraocular pressure ≥ 36mmHg (unmedicated) in either eye (individuals who are excluded for this criterion are not allowed to attempt requalification), or use of more than two ocular hypotensive medications within 30 days of screening. Note: fixed dose combination medications, for the purpose of this exclusion criterion, count as one medication. However, subjects currently taking 2 fixed dose combination products are excluded.
Treatment-naïve subjects.
Prior treatment with GANFORT® topical eye drops where the subjects IOP did not achieve the target IOP and was considered either a therapeutic failure or to have insufficient response. Subjects currently (immediately prior to screening visit) being treated with GANFORT® are excluded from the study.
Known hypersensitivity to any component of the investigational formulations to be used (e.g., benzalkonium chloride) or to fluorescein.
Previous glaucoma intraocular surgery, including SLT or ALT in either eye.
Refractive surgery in either eye (e.g., radial keratotomy, PRK, LASIK, corneal cross-linking, keratoplasty).
Ocular trauma within the six months prior to screening, or ocular surgery or non-refractive laser treatment within the three months prior to screening.
Recent or current evidence of ocular infection or inflammation in either eye. Current evidence of clinically significant blepharitis, conjunctivitis, keratitis, current evidence or history of herpes simplex or zoster keratitis in either eye at screening.
Use of ocular medication in either eye of any kind within 30 days of screening and throughout the study, with the exception of a) ocular hypotensive medications which must have been the same medication for 30 days prior to screening (which must be washed out according to the provided schedule), b) lid scrubs (which may be used prior to, but not after, screening), c) lubricating drops for dry eye (which may be used throughout the study), as prescribed by the Investigator.
Mean central corneal thickness greater than 620μm at screening.
Any abnormality preventing reliable Goldmann applanation tonometry of either eye (e.g., keratoconus).
Systemic:
Clinically significant abnormalities in laboratory tests at screening.
Known hypersensitivity or contraindication to GANFORT® (Appendix 3 Marketed Product Medication Information Section 4.3) and to β-adrenoceptor antagonists (e.g. Chronic obstructive pulmonary disease or bronchial asthma; abnormally low blood pressure or heart rate; second or third-degree heart block or congestive heart failure, cardiac failure, cardiac shock and severe diabetes).
Clinically significant systemic disease which might interfere with the study.
Participation in any investigational study within 30 days prior to screening.
Systemic medication including corticosteroid containing drugs that could have a substantial effect on IOP which HAVE NOT been maintained at a consistent dose and regime within 30 days prior to screening, and are anticipated to change in dose and/or regime during the study.
Use of topical steroid containing medications on the face or in or around the eyes will exclude the subject (see Section 5.6 Concomitant Medications).
Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable and highly effective form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal (1 year without menses with appropriate clinical profile, e.g. age appropriate, > 45 years in the absence of HRT. In questionable cases the subject must have FSH value > 40mIU/mL and an estradiol value < 40pg/mL (< 140pmol/L)) or three months post-surgical sterilization.
Vulnerable subjects such as minors, adults under legal protection or unable to express their consent (e.g. hospitalized persons in coma), persons deprived of liberty (prisoners from jails), or persons subject to psychiatric care.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michelle Senchyna
Organizational Affiliation
Aerie Pharmaceuticals Inc.
Official's Role
Study Director
Facility Information:
Facility Name
State Hospital - University Medical Center Academical Department of Ophthalmology
City
Graz
Country
Austria
Facility Name
Albertgasse 39/10+11
City
Vienna
Country
Austria
Facility Name
Hanusch Hospital
City
Vienna
Country
Austria
Facility Name
UZ Leuven, campus Gasthuisberg, Herestraat 49, 3000 Leuven
City
Leuven
Country
Belgium
Facility Name
Faculty Hospital Brno Eye Department
City
Brno
ZIP/Postal Code
62500
Country
Czechia
Facility Name
Glaucoma center Oční klinika VFN a 1. LF UK
City
Praha
ZIP/Postal Code
12808
Country
Czechia
Facility Name
Ophthalmology Service Centre Francois Xavier Michelet CHU Pellegrin
City
Bordeaux
Country
France
Facility Name
Centre ophtalmologique Pole vision val d'ouest
City
Ecully
Country
France
Facility Name
Ophthalmology Service - Batiment R Hospital de la Croix-Rousse
City
Lyon
Country
France
Facility Name
CHU de Nantes-Hospital Hotel Dieu Ophthalmology Service
City
Nantes
Country
France
Facility Name
Ophthalmology department Necker University Hospital-Enfants Malades
City
Paris
Country
France
Facility Name
University Medical Center Freiburg, Eye Center,Killianstr.5, Freiburg i. Breisgau
City
Freiburg
ZIP/Postal Code
79106
Country
Germany
Facility Name
Department of Ophthalmology Clinical Johannes Gutenberg-University Mainz
City
Mainz
Country
Germany
Facility Name
Universitats-Augenklinik, Studienzentrum/Clinical Trials in Opthalmology (CTO)
City
Münster
Country
Germany
Facility Name
University Eye Hospital Tuebingen, STC eyetrial at the center for Ophthalmolgy
City
Tuebingen
Country
Germany
Facility Name
Augenarztpraxis Dr. Andreas Bayer
City
Weilheim
Country
Germany
Facility Name
Budapest Retina Associates
City
Budapest
Country
Hungary
Facility Name
Department of Ophthalmology Semmelweis University
City
Budapest
Country
Hungary
Facility Name
University of Debrecen, Clinical Center, Ophthalmology Department
City
Debrecen
Country
Hungary
Facility Name
Clinexpert Gyongyos Kft.
City
Heves
Country
Hungary
Facility Name
Ganglion Medical Center
City
Pécs
Country
Hungary
Facility Name
University of Szeged, Department of Ophthalmology
City
Szeged
Country
Hungary
Facility Name
Markusovszky University Teaching Hospital
City
Szombathely
Country
Hungary
Facility Name
Ophthalmic Clinic DiNOGMI University Hospital San Martino
City
Genova
Country
Italy
Facility Name
Dept. Ophthalmology, San Raffaele Hospital
City
Milano
Country
Italy
Facility Name
ASST Fatebenefratelli Sacco P.O.L.Sacco
City
Milan
Country
Italy
Facility Name
ASST Santi Paolo e Carlo - Ophthalmic Clinic
City
Milan
Country
Italy
Facility Name
Department of Medicine and Surgery University of Parma
City
Parma
Country
Italy
Facility Name
Ophthamic Clinic of the University of Pavia, IRCCS Foundation San Matteo Policlinic
City
Pavia
Country
Italy
Facility Name
AOU Pisana Hospital of Cisanello
City
Pisa
Country
Italy
Facility Name
G.B.Bietti Foundation - IRCCS
City
Rome
Country
Italy
Facility Name
Senese University Hospital
City
Siena
Country
Italy
Facility Name
S.C.U Oculistica, Azienda Ospedaliero Universitaria, Città della Salute e della Scienza
City
Torino
ZIP/Postal Code
10146
Country
Italy
Facility Name
University Eye Clinic Ospedale Maggiore
City
Trieste
Country
Italy
Facility Name
Politecnico Gianbattista Rossi AOUI Ospedale Borgo Roma
City
Verona
Country
Italy
Facility Name
Signes Ozolinas Doctor Practice in Ophthalmology
City
Jelgava
Country
Latvia
Facility Name
Latvian American Eye Centre (LAAC)
City
Riga
Country
Latvia
Facility Name
P.Stradins Clinical University Hospital, Ophthalmology Clinic
City
Riga
Country
Latvia
Facility Name
Riga East University hospital, In-patient Department "Biķernieki", Ophthalmology Clinic
City
Riga
Country
Latvia
Facility Name
Professor K. Gibinski University Clinical Centre
City
Katowice
Country
Poland
Facility Name
Department of Diagnostics and Microsurgery of Glaucoma
City
Lublin
Country
Poland
Facility Name
Military Institute of Medicine Klinika Okulistyki
City
Warsaw
Country
Poland
Facility Name
Ophthalmic Clinic Jasne Blonia
City
Łódź
Country
Poland
Facility Name
Centro de Oftalmologia Barraquer
City
Barcelona
Country
Spain
Facility Name
Hospital General de Catalunya Ophthalmology Department
City
Barcelona
Country
Spain
Facility Name
Hospital QuironSalud Barcelona
City
Barcelona
Country
Spain
Facility Name
Institut Catala de retina (ICR) Glaucoma and Investigation Department
City
Barcelona
Country
Spain
Facility Name
Hospital General del S.A.S. de Jerez de la Frontera
City
Cádiz
ZIP/Postal Code
11407
Country
Spain
Facility Name
Hospital Universitario Reina Sofía de Córdoba
City
Córdoba
Country
Spain
Facility Name
Centro de Ojos de la Coruña
City
La Coruña
Country
Spain
Facility Name
Hospital Universitario Virgen Macarena Ophthalmology Department
City
Sevilla
Country
Spain
Facility Name
Hospital Universitario de Torrevieja Ophthalmology Department
City
Torrevieja
Country
Spain
Facility Name
FISABIO-Oftalmología Médica
City
Valencia
Country
Spain
Facility Name
Ophthalmology Department Hospital Universitario Rio Hortega
City
Valladolid
Country
Spain
Facility Name
Hospital Clinico Universitario Lozano Blesa Zaragoza Ophthalmology department
City
Zaragoza
Country
Spain
Facility Name
Hospital Universitario Miguel Servet Ophthalmology Department
City
Zaragoza
Country
Spain
Facility Name
City Hospitals Sunderland NHS Foundation Trust Sunderland Eye Infirmary
City
Sunderland
State/Province
Tyne And Wear
Country
United Kingdom
Facility Name
NHS Grampian Aberdeen Royal Infirmary
City
Aberdeen
Country
United Kingdom
Facility Name
Cambridge University Hospitals NHS Trust
City
Cambridge
Country
United Kingdom
Facility Name
Ophthalmology Department, Queen Alexandra Hospital
City
Cosham
Country
United Kingdom
Facility Name
Mid-Cheshire Hospitals NHS Foundation Trust
City
Crewe
Country
United Kingdom
Facility Name
Northwest Anglia NHS Foundation trust Hinchingbrooke Hospital
City
Huntingdon
Country
United Kingdom
Facility Name
Guy's & St Thomas' NHS Foundation Trust Glaucoma Research Area
City
London
Country
United Kingdom
Facility Name
King's College Hospital
City
London
Country
United Kingdom
Facility Name
Moorfields Eye Hospital NHS
City
London
Country
United Kingdom
Facility Name
Western Eye Hospital
City
London
Country
United Kingdom
Facility Name
Royal Hallamshire Hospital
City
Sheffield
Country
United Kingdom
Facility Name
Queen Mary Hospital, King's College Hospital NHS
City
Sidcup
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
We'll reach out to this number within 24 hrs